

North Central Cancer Treatment Group

N0779: Phase II Study of Vorinostat (SAHA) in Combination with Bortezomib (PS-341) in Patients with Recurrent Glioblastoma Multiforme

Update 1 – November 21, 2008

Summary

- Administrative/editorial changes.

Replacement pages are included. Please incorporate into the protocol and keep this update with your protocol.

Title page Updated to reflect the addition of Update 1 and revised NCI version date.

Appendix IB **Consent Form**
Page 2: The second sentence of the first paragraph in the section “Before surgery” has been corrected as follows:

Bortezomib will be given into a vein on the day of **just before** surgery following vorinostat.